



## **Cosmo Pharmaceuticals announces a change in its board of directors**

- *retirement of Dr. Hans Christoph Tanner as non-executive director*
- *proposal for the appointment of Mr. David Maris as new non-executive board member*

**Dublin, Ireland – 10 May 2021:** Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) today announced the resignation, due to his retirement, of Dr. Hans Christoph Tanner as a non-executive board member and the proposal for the appointment of Mr. David Maris as a new non-executive board member, both to take effect from the next AGM on the 28<sup>th</sup> of May.

Dr. Tanner, who organized the only private financing round of Cosmo in 2005 and then joined the company as CFO to take it public on SIX in 2007, has been a board member since 2007 and has already retired from his executive positions in February 2020. Dr. Tanner said: *“Cosmo is embarking on a series of new developments that need undivided attention and some fresh input. Therefore, I have decided to retire from my non-executive board position. My time at Cosmo has been thrilling and I wish the company every success for the future”*.

Mauro Ajani, Chairman of Cosmo, said: *“I am thankful to Chris for his continued and relentless support of the years. He has been a key factor in the shaping of the company and I am very grateful for that”*.

It is proposed to replace Dr. Tanner as a non-executive director with Mr. Maris at the next AGM set for May 28, 2021.

Mr. Maris is a private investor with Phalanx Investment Partners, LLC, an investment advisor, since January 2020, and a member of the board of directors of Amphastar Pharmaceuticals (NASDAQ: AMPH). He also serves as a member of the American Finance Association and National Association of Corporate Directors. Mr. Maris has been a managing director and equity research analyst at Wells Fargo Securities, LLC, an investment bank, from December 2015 up to December 2019. Before serving at Wells Fargo Securities, LLC, Mr. Maris served as a managing director and equity research analyst at Bank of Montreal, an investment bank, in the period from January 2013 to December 2015. Prior to serving Bank of Montreal and Wells Fargo Securities, LLC, he served as a healthcare industry equity analyst for several other investment banks, including Aros Securities, Bear Stearns, Credit Suisse, Bank of America, and Credit Agricole - CLSA. Mr. Maris is a U.S. national and holds a B.A. from the University of Delaware and an M.B.A. from Vanderbilt University’s Owen Graduate School of Management.

### **About Cosmo Pharmaceuticals**

Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has a partnership with Medtronic for the global distribution of GI Genius™ its artificial intelligence device that uses artificial intelligence to help detect potential signs of colon cancer. Cosmo has licensed Aemcolo® to Red Hill Biopharma Ltd. for the US and has licensed Relafalk® to Dr. Falk GmbH for the EU and other countries. For additional information on Cosmo and its products please visit the Company’s website: [www.cosmopharma.com](http://www.cosmopharma.com)

**Calendar**

Annual General Meeting, Amsterdam	May 28, 2021
Half-Year 2021 Report	July 30, 2021
Investora Conference, Zurich	September 15/16, 2021

**Contact**

Niall Donnelly, CFO & Head of Investor Relations  
Cosmo Pharmaceuticals N.V.  
Tel: +353 1 817 03 70  
[ndonnelly@cosmopharma.com](mailto:ndonnelly@cosmopharma.com)